1. Articles in category: Information

    1-24 of 253 1 2 3 4 ... 9 10 11 »
    1. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    2. Radical Surgery Improves Survival in Patients with Stage 4 Neuroblastoma.

      Radical Surgery Improves Survival in Patients with Stage 4 Neuroblastoma.

      World J Surg. 2017 Nov 10;:

      Authors: Vollmer K, Gfroerer S, Theilen TM, Bochennek K, Klingebiel T, Rolle U, Fiegel H

      Abstract BACKGROUND: Neuroblastoma (NBL) is the most common extracranial solid tumor in children. Despite a good overall prognosis in NBL patients, the outcome of children with stage 4 disease, even with multimodal intensive therapy, remains poor.

      Read Full Article
      Mentions: Surgery
    3. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.

      MAbs. 2017 Nov 09;:0

      Authors: Mueller I, Ehlert K, Endres S, Pill L, Siebert N, Kietz S, Brock P, Garaventa A, Valteau-Couanet D, Janzek E, Hosten N, Zinke A, Barthlen W, Varol E, Loibner H, Ladenstein R, Lode HN

      Read Full Article
    4. MicroRNA profiles in neuroblastoma: Differences in risk and histology groups.

      MicroRNA profiles in neuroblastoma: Differences in risk and histology groups.

      Asia Pac J Clin Oncol. 2017 Nov 08;:

      Authors: Ergin K, Aktaş S, Altun Z, Dınız G, Olgun N

      Abstract AIM: To determine the miRNA expression profiles of neuroblastomas with different clinical and histological characteristics. METHODS: In this study 24 samples from 17 patients, paraffin blocks were used.

      Read Full Article
    5. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

      Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

      Neoplasia. 2017 Oct 26;19(12):982-990

      Authors: Rosswog C, Schmidt R, Oberthuer A, Juraeva D, Brors B, Engesser A, Kahlert Y, Volland R, Bartenhagen C, Simon T, Berthold F, Hero B, Faldum A, Fischer M

      Read Full Article
      Mentions: MYCN
    6. Expression of Truncated Neurokinin-1 Receptor in Childhood Neuroblastoma is Independent of Tumor Biology and Stage.

      Expression of Truncated Neurokinin-1 Receptor in Childhood Neuroblastoma is Independent of Tumor Biology and Stage.

      Anticancer Res. 2017 11;37(11):6079-6085

      Authors: Pohl A, Kappler R, Mühling J, VON Schweinitz D, Berger M

      Abstract BACKGROUND: Neuroblastoma is an embryonal malignancy arising from the aberrant growth of neural crest progenitor cells of the sympathetic nervous system.

      Read Full Article
      Mentions: Staging MYCN
    7. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    8. Comparison of diagnosing and staging accuracy of Pet (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

      Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

      J Huazhong Univ Sci Technolog Med Sci. 2017 Oct;37(5):649-660

      Authors: Xia J, Zhang H, Hu Q, Liu SY, Zhang LQ, Zhang A, Zhang XL, Wang YQ, Liu AG

      Read Full Article
      Mentions: Staging MIBG
    9. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      Pediatr Hematol Oncol. 2017 Oct 17;:1-11

      Authors: Coughlan D, Gianferante M, Lynch CF, Stevens JL, Harlan LC

      Abstract BACKGROUND: Childhood neuroblastoma describes a heterogeneous group of extracranial solid tumors, that are treated per risk profile. We sought to describe treatment patterns and survival using population-based data from throughout the United States.

      Read Full Article
      Mentions: Treatment COG MYCN
    10. LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      Oncotarget. 2017 Sep 12;8(39):65620-65626

      Authors: Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, Yang L, Yan L

      Abstract Previous genome-wide association and validation studies suggest that LIM domain only 1 (LMO1) gene polymorphisms affect neuroblastoma susceptibility.

      Read Full Article
    11. Zebrafish as a model to study neuroblastoma development.

      Zebrafish as a model to study neuroblastoma development.

      Cell Tissue Res. 2017 Oct 13;:

      Authors: Casey MJ, Stewart RA

      Abstract Neuroblastoma is a pediatric solid tumor arising from embryonic neural crest progenitor cells that normally generate the peripheral sympathetic nervous system.

      Read Full Article
      Mentions: ALK
    12. Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

      J Pediatr Surg. 2017 Sep 11;:

      Authors: Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G

      Abstract BACKGROUND/PURPOSE: The impact of abdominal topography and surgical technique on resectability and local relapse pattern of relapsed abdominal high-risk neuroblastoma (R-HR-NB) is not clearly defined.

      Read Full Article
      Mentions: Treatment Relapse
    13. Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Genetic Variations of GWAS-Identified Genes and Neuroblastoma Susceptibility: a Replication Study in Southern Chinese Children.

      Transl Oncol. 2017 Oct 09;10(6):936-941

      Authors: He J, Zou Y, Wang T, Zhang R, Yang T, Zhu J, Wang F, Xia H

      Abstract Neuroblastoma is one of the most commonly diagnosed solid cancers for children, and genetic factors may play a critical role in neuroblastoma development.

      Read Full Article
    14. Diagnosis of pediatric neuroblastoma by urine cytology: A case report.

      Diagnosis of pediatric neuroblastoma by urine cytology: A case report.

      Diagn Cytopathol. 2017 Oct 06;:

      Authors: Nishikawa S, Noguchi H, Tokumitsu T, Ohno A, Moriguchi-Goto S, Maekawa K, Asada Y, Moritake H, Kinoshita M, Yamada A, Takamura K, Sato Y

      Abstract Neuroblastomas are embryonal tumors arising from the neuronal crest cells of the synaptic nervous system. Findings from aspiration cytology have been reported, but there have been no reports of urine cytology findings.

      Read Full Article
    15. Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma.

      Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma.

      Pediatr Hematol Oncol. 2017 Oct 04;:1-8

      Authors: Okamoto Y, Kodama Y, Nishikawa T, Rindiarti A, Tanabe T, Nakagawa S, Yoshioka T, Takumi K, Kaji T, Kawano Y

      Read Full Article
      Mentions: Treatment MIBG
    16. MicroRNAs in neuroblastoma: Biomarkers with Therapeutic potential.

      MicroRNAs in neuroblastoma: Biomarkers with Therapeutic potential.

      Curr Med Chem. 2017 Oct 03;:

      Authors: Galardi A, Colletti M, Businaro P, Quintarelli C, Locatelli F, Di Giannatale A

      Abstract BACKGROUND: Neuroblastoma is the most common extracranial solid tumor in infancy. The majority of children have a disseminated disease at diagnosis with bone marrow as the most common site of metastasis. Although several prognostic factors have been defined (i.e.

      Read Full Article
    17. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Carcinogenesis. 2017 Aug 29;:

      Authors: Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M

      Read Full Article
    18. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma

      Pediatric cancers such as neuroblastoma are thought to involve a dysregulation of embryonic development. However, it has been difficult to identify the critical events that trigger tumorigenesis and differentiate them from normal development. In this study, we report the establishment of a spheroid culture method that enriches early-stage tumor cells from TH-MYCN mice, a preclinical model of neuroblastoma.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    19. Researchers Identify Gene Variants Linked to a High-Risk Children's Cancer

      Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery, in the MMP20 gene, may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    20. Researchers identify gene variants linked to a high-risk children's cancer

      Researchers identify gene variants linked to a high-risk children's cancer

      ( Children's Hospital of Philadelphia ) Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    21. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    22. When good immune cells turn bad

      When good immune cells turn bad

      Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster neuroblastoma, a pediatric cancer, and have demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.

      Read Full Article
    23. Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

      Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.

      Oncol Lett. 2017 Sep;14(3):3363-3370

      Authors: Gnanamony M, Antony R, Fernández KS, Jaime L, Lin J, Joseph PA, Gondi CS

      Abstract Neuroblastoma accounts for >15% of cancer-associated mortalities of children in the USA. Despite aggressive treatment regimens, the long-term survival for these children remains <40%.

      Read Full Article
      Mentions: Treatment
    1-24 of 253 1 2 3 4 ... 9 10 11 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (3 articles) MYCN
    2. (1 articles) Antibody
    3. (1 articles) Immunotherapy
  4. General Informations in the News

    1. (1 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Surgery